CollPlant Biotechnologies

Historical price data

CollPlant Biotechnologies' mission is to leverage its unique, plant-derived recombinant human collagen (rhCollagen) as a foundational biomaterial to advance regenerative and aesthetic medicine. The company's key achievement is the establishment of a scalable GMP manufacturing platform using genetically engineered tobacco plants, producing Type I and Type III human collagen with high purity and consistency. Its strategy focuses on developing an internal product pipeline in aesthetics and wound care while actively partnering its rhCollagen and bio-inks with leading firms in the 3D bioprinting and medical device sectors. Despite being a micro-cap company facing clinical and financial challenges, its technology represents a significant long-term opportunity in the shift towards sustainable, non-animal biomaterials.

Proprietary plant-based platform using genetically engineered tobacco plants to produce recombinant human Type I and Type III collagen (rhCollagen) with correct triple-helical structure, offering a pure, scalable, and animal-free alternative to traditional collagen sources.

CollPlant competes with large medical aesthetics and wound care companies, traditional animal collagen extractors, and other recombinant collagen producers. Its primary differentiation is its scalable plant-based production system yielding human-identical collagen, though it must overcome cost barriers and market inertia to displace established products.